The Prognostic and Immunotherapeutic Significanceof NCAPD2 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma

Author:

Ma Wenjing1,Tian Yao2,Shen Wanbo3,Song Zhengrui3,Yang Bo3,Ye Daowen4

Affiliation:

1. University of Chinese Academy of Sciences

2. Qilu Pharmaceutical Co., Ltd

3. The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital

4. Quanjiao People 's Hospital

Abstract

Abstract Background Present studies indicated that NCAPD2 has emerged as an essential participant of condensin I involved in the mitotic chromosome assembly and dissociation. Simultaneously, NCAPD2 has an enormous potent to interpret the tumor progression in a broader perspective. Due to the superficial comprehensive analysis of NCAPD2 in pan-cancer, lacking of detailed studies was to explore the underlying pathogenesis and the potential regulatory mechanism. Herein, this study systematically provided the prognostic landscape visualization of NCAPD2 in pan-cancer, and further investigate the function and the correlation with immune infiltration characteristics in hepatocellular carcinoma (HCC). Method In this study, using the online databases TCGA, TIMER2.0, OPENTARGET, GeneMANIA, HPA, UCSC, TCIA. This analysis suggested that the relevance between NCAPD2 and oncogenesis, progression, prognosis, methylation, immune infiltration and function. Subsequently, RT-qPCR, western blotting assays were performed to detect the NCAPD2 expression. Additionally, the proliferation of NCAPD2 silenced cells was evaluated using BrdU assay. Transwell assays further confirmed the effect of knock down NCAPD2 on migration and invasion capacity. Flow cytometry assay was finally performed to assess cell cycle and apoptosis in indicated cells. Result NCAPD2 was aberrant active in multiple cancers. NCAPD2 upregulation was related with poor prognosis in pan-cancer. Meanwhile, NCAPD2 gene mutation, the methylation level of NCAPD2 promoter and MSI increase occurred in a series of cancers. In addition, the results exhibited that a significant association between abnormal expression of NCAPD2 and immune infiltration cells and immune therapy response in HCC. Furthermore, this study clarified the utility of NCAPD2 that knock down its expression could result in suppressing proliferation, invasion and migration capacity, and induce the accumulation of G0/G1 cells and the apoptosis occurrence in HCC cells. Conclusion This study revealed that NCAPD2 could participate in the carcinogenic progression of various cancers. It used as a potential diagnostic and prognostic marker in pan-cancer, especially HCC patients, and contributed to the NCAPD2-based estimation of immune-therapy response for HCC, which might provide a new strategies into immune therapy and precision medicine.

Publisher

Research Square Platform LLC

Reference49 articles.

1. Estimated Projection of US Cancer Incidence and Death to 2040;Rahib L;JAMA Netw open,2021

2. Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity;Manzella G;Nat Commun,2020

3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a cancer journal for clinicians 2021, 71(1):7–33.

4. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer;Forde PM;N Engl J Med,2018

5. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC;Herbst RS;N Engl J Med,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3